Reed N S, Poole C J, Coleman R, Parkin D, Graham J D, Kaye S B, Ostrowski J, Duncan I, Paul J, Hay A
Beatson Oncology Centre, Western Infirmary, EORTC Gynaecological Cancer Group, Dumbarton Road, Glasgow G11 6NT, UK.
Eur J Cancer. 2006 Jan;42(2):179-85. doi: 10.1016/j.ejca.2005.09.022. Epub 2005 Dec 6.
The management of older and unfit women with advanced ovarian cancer requires post-operative chemotherapy but many of these patients are not suitable for high-dose cisplatin-based regimes. Carboplatin has been an easier alternative and can be given in the ambulatory setting. Historical data suggests that oral alkylating agents to be just effective with similar efficacy. In this study we have compared platinum-based carboplatin to the alkylating agent treosulfan in a population unfit to receive high-dose cisplatin. The trial randomised patients to either intravenous carboplatin or treosulfan as single agent. The trial was stopped prematurely after the interim analysis showed improved survival and response rates in the carboplatin arm. We conclude that carboplatin is a safe and effective drug in a population that is unfit for high-dose cisplatin. Treosulfan showed limited activity but may be considered along with other oral drugs in limited circumstances. With the exception of myelosuppression, toxicity was mild in both arms. Carboplatin remains the gold standard in this older and less fit group of patients.
